Literature DB >> 12495792

Characteristics, beliefs, and practices of community clinicians trained to provide manual-guided therapy for substance abusers.

Samuel Ball1, Ken Bachrach, Jacqueline DeCarlo, Chris Farentinos, Melodie Keen, Terence McSherry, Douglas Polcin, Ned Snead, Richard Sockriter, Paulen Wrigley, Lucy Zammarelli, Kathleen Carroll.   

Abstract

The successful dissemination of empirically supported addiction therapies to community providers requires an appreciation of the characteristics of those practitioners who might be willing participants in this process of technology transfer. Clinicians (N = 66) from 11 community treatment programs associated with six research-clinic partnerships of the National Drug Abuse Clinical Trials Network volunteered to be trained in Motivational Interviewing or Motivational Enhancement Therapy (MET/MI) and were assessed prior to training. The sample of clinicians was heterogeneous in education and credentials, had a high level of counseling experience, reported using a wide range of counseling techniques and orientations, but had limited prior exposure to MET/MI or to the use of treatment manuals of empirically supported therapies. In general, many of the clinicians reported beliefs and techniques that were consistent with their stated theoretical orientation and recovery status. Relatively few participants reported relying on one dominant orientation or set of techniques.

Entities:  

Mesh:

Year:  2002        PMID: 12495792     DOI: 10.1016/s0740-5472(02)00281-7

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  52 in total

Review 1.  Evidence-based practices for substance use disorders.

Authors:  Mark P McGovern; Kathleen M Carroll
Journal:  Psychiatr Clin North Am       Date:  2003-12

Review 2.  MET meets the real world: design issues and clinical strategies in the Clinical Trials Network.

Authors:  Kathleen M Carroll; Chris Farentinos; Samuel A Ball; Paul Crits-Christoph; Bryce Libby; Jon Morgenstern; Jeanne L Obert; Doug Polcin; George E Woody
Journal:  J Subst Abuse Treat       Date:  2002-09

3.  The Short Inventory of Problems - revised (SIP-R): psychometric properties within a large, diverse sample of substance use disorder treatment seekers.

Authors:  Brian D Kiluk; Jessica A Dreifuss; Roger D Weiss; Jon Morgenstern; Kathleen M Carroll
Journal:  Psychol Addict Behav       Date:  2012-05-28

4.  We don't train in vain: a dissemination trial of three strategies of training clinicians in cognitive-behavioral therapy.

Authors:  Diane E Sholomskas; Gia Syracuse-Siewert; Bruce J Rounsaville; Samuel A Ball; Kathryn F Nuro; Kathleen M Carroll
Journal:  J Consult Clin Psychol       Date:  2005-02

Review 5.  Theory-based active ingredients of effective treatments for substance use disorders.

Authors:  Rudolf H Moos
Journal:  Drug Alcohol Depend       Date:  2006-11-28       Impact factor: 4.492

6.  One small step for manuals: Computer-assisted training in twelve-step facilitation.

Authors:  Diane E Sholomskas; Kathleen M Carroll
Journal:  J Stud Alcohol       Date:  2006-11

7.  Strategies to encourage adoption in multisite clinical trials.

Authors:  Joseph Guydish; Barbara Tajima; Sarah Turcotte Manser; Martha Jessup
Journal:  J Subst Abuse Treat       Date:  2006-11-22

8.  Organizational characteristics of drug abuse treatment programs for offenders.

Authors:  Christine E Grella; Lisa Greenwell; Michael Prendergast; David Farabee; Elizabeth Hall; Jerome Cartier; William Burdon
Journal:  J Subst Abuse Treat       Date:  2007-03-09

9.  Research participation and turnover intention: An exploratory analysis of substance abuse counselors.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2007-03-21

10.  Does treatment fidelity predict client outcomes in 12-Step Facilitation for stimulant abuse?

Authors:  Joseph Guydish; Barbara K Campbell; Jennifer K Manuel; Kevin L Delucchi; Thao Le; K Michelle Peavy; Dennis McCarty
Journal:  Drug Alcohol Depend       Date:  2013-11-04       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.